Navigation Links
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Date:12/12/2011

.

Patients enrolled in the STARS E-III (Japanese and Taiwanese patients) and STARS J-V (Japanese patients) studies were randomized to receive either oral edoxaban 30 mg once daily or subcutaneous enoxaparin 20 mg (2,000 IU) twice daily for 11 to 14 days, in line with standard clinical practice in Japan. [i,ii]

"We are pleased to see positive outcomes with edoxaban in this patient population," said Dr. Kazunori Hirokawa, Global Head of R&D Unit, Daiichi Sankyo Co., Ltd. "These results further support the safety and efficacy of edoxaban in the prevention of DVT and PE following major orthopedic surgery. Daiichi Sankyo remains committed to developing edoxaban in our global clinical trials program."

About Edoxaban
Edoxaban is a once-daily oral anticoagulant that directly inhibits Factor Xa, an important factor in the coagulation process. Edoxaban is currently available only in Japan, licensed for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty, total hip arthroplasty and hip fracture surgery. Daiichi Sankyo continues to develop edoxaban at a global level as a potential new treatment for stroke prevention in atrial fibrillation, and the treatment and prevention of recurrent VTE. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to study these compounds in humans.

About the Pooled STARS Analysis
The analysis drew data from two Phase III comparative studies, STARS E-III and STARS J-V.

  • The STARS E-III[i] study was a double-blind, enoxaparin-controlled, randomized study comparing edoxaban 30 mg once daily and enoxaparin 20 mg (2,000 IU) in the prevention of VTE in a total of 716 Japanese and Taiwanese patients undergoing TKA[i].
  • The STARS J-V[ii] study was a double-blind, enoxaparin-controlled, randomized study comparing ed
    '/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
2. Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
3. Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DIEGO , July 30, 2014   ... biotech company that designs and develops novel diagnostics ... of cancer, announced today the completion of a ... financing included new investors RusnanoMedInvest (RMI) and Arcus ... and Pfizer Venture Investments, as well as undisclosed ...
(Date:7/30/2014)... , 30. Juli 2014 ... ein führender Anbieter im Bereich Atemtherapie- und ... des Landgerichts München in Deutschland anfechten werden. ... bestimmten Masken ein Patent von ResMed verletze. ... in wichtigen Ländern gegen verschiedene Patente von ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... growth driven by strong performance across the portfolio, particularly ... ® (denosumab) and XGEVA ® (denosumab). ... by higher revenues and a significant increase in the ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... SUNNYVALE, Calif., Dec. 28, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its president and chief executive officer, ... 29th Annual J.P. Morgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... and non-woven fabric made from 100% natural PurCotton® products ... was recently held by Winner Medical and Cotton Incorporated ... in a high footprint shopping mall in Shanghai. ...
Cached Medicine Technology:Accuray Incorporated's CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 3Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 4
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... 2014 Naomi Fried, PhD, and ... of Directors of the American Telemedicine Association (ATA). ... which has a mission to promote professional, ethical ... and information technology. , “Both Naomi Fried and ... extraordinary expertise and are well known experts in ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Clues to whether a person is ... test, a new study suggests. Chemical changes to a ... help spur suicidal thoughts and behaviors, the study,s authors explained. ... doctors to a patient,s risk for suicide, they said. ... have been stymied in our prevention efforts because we have ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... This news release is available in French . ... Inserm, led by Claude Gronfier (Inserm Unit 846: Stem ... conducted a study under real conditions on the body ... Concordia. The researchers have shown that a particular kind ... biological rhythms are correctly synchronised despite the absence of ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... recently discovered genes from an ancient wheat variety have led ... ,In a recent set of papers published in the ... as Nax1 and Nax2. The genes work by excluding salt ... the other from the leaves. The discovery of the two ...
... is a neighborhood which renders immense potential to walk around, ... revealed in a survey conducted by// Ethan Berke of Dartmouth ... for publication in the March issue of American Journal of ... group of 65-97. Some of the parameters that were analyzed ...
... more slowly in women and older adults, a new study at ... to the skin heal more quickly in women than in men, ... inside the mouth," said Dr. Phillip Marucha, head of periodontics at ... of age, men's mouth wounds heal faster than women's." ...
... practice guidelines for diagnosis and management of venous thromboembolism.// ... clotting in the veins. ,Key elements of ... rules to establish pretest probability of deep vein thrombosis ... and the utility of various diagnostic tools such as ...
... the application filed before the Hon’ble Supreme Court, the ... to ST candidates in the All India Quota seats ... session 2007-08. While disposing of this application for directions ... case Vs Union of India, WP 18/2006, Hon’ble Supreme ...
Cached Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Medicine Products: